Press release – Collaboration with Anagenesis on DMD

Dec 6, 2018 | Press releases

Together with Anagenesis Biotechnologies, Ksilink reachs first exit point in the field of Duchenne Muscular Disease. A major industrial Venture Fund invests into  Anagenesis with a € 3 M seed funding and subsequently up to € 15 M round A investment within the next 18 months.

Click here to download the press release.

Share This